Posted by Michael Wonder on 10 Nov 2021
NICE terminates appraisal of new, first in class radioenhancer hafnium oxide nanoparticle
10 November 2021 - NBTXR3 is used to treat patients with sarcoma.
NICE is unable to make a recommendation on the use of NBTXR-3 for the treatment of patients with advanced soft tissue sarcoma. This is because Nanobiotix did not provide an evidence submission.
NICE will review this decision if Nanobiotix decides to make a submission.
